[
  {
    "title": "百奥泰(688177.SH)：BAT1806(托珠单抗)注射液在美国FDA上市许可申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/12/09205537202903.shtml",
    "datetime": "2022-12-09 20:55:26",
    "code": "688177"
  },
  {
    "title": "百奥泰2022年前三季度亏损2.56亿同比亏损增加 授权许可收入减少",
    "href": "http://stock.jrj.com.cn/2022/10/26225037087747.shtml",
    "datetime": "2022-10-26 22:50:54",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：第三季度净亏损8649.175万元",
    "href": "http://stock.jrj.com.cn/2022/10/26161637085707.shtml",
    "datetime": "2022-10-26 16:16:28",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：BAT1806(托珠单抗)注射液在欧洲EMA上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2022/09/30193837035020.shtml",
    "datetime": "2022-09-30 19:38:56",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：注射用BAT8007获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/09/23161037017271.shtml",
    "datetime": "2022-09-23 16:10:56",
    "code": "688177"
  },
  {
    "title": "止盈转亏 百奥泰2022年半年度净亏损1.69亿元",
    "href": "http://stock.jrj.com.cn/2022/08/24090536928928.shtml",
    "datetime": "2022-08-24 09:05:49",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177)：注射用BAT8008获得临床试验批准",
    "href": "http://stock.jrj.com.cn/2022/08/24085836928903.shtml",
    "datetime": "2022-08-24 08:58:40",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：拟使用不超1亿元闲置募集资金暂时补充流动资金",
    "href": "http://stock.jrj.com.cn/2022/08/23200536927641.shtml",
    "datetime": "2022-08-23 20:05:16",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：注射用BAT8008获批临床试验",
    "href": "http://stock.jrj.com.cn/2022/08/23170336926601.shtml",
    "datetime": "2022-08-23 17:03:59",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：上半年净亏损1.69亿元",
    "href": "http://stock.jrj.com.cn/2022/08/23170136926605.shtml",
    "datetime": "2022-08-23 17:01:02",
    "code": "688177"
  },
  {
    "title": "百奥泰及相关人员因财务核算等方面问题收警示函",
    "href": "http://stock.jrj.com.cn/2022/08/22103636920467.shtml",
    "datetime": "2022-08-22 10:36:28",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：截至8月8日累计收到增值税留抵退税4149.46万元",
    "href": "http://stock.jrj.com.cn/2022/08/08161436879051.shtml",
    "datetime": "2022-08-08 16:14:51",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：累计获得政府补助款项共1253.66万元",
    "href": "http://stock.jrj.com.cn/2022/08/05162736873892.shtml",
    "datetime": "2022-08-05 16:27:43",
    "code": "688177"
  },
  {
    "title": "百奥泰：预计2022年半年度亏损1.90亿至1.60亿元 净利润同比下降7362.44%至6215.74%",
    "href": "http://stock.jrj.com.cn/2022/08/01100736858162.shtml",
    "datetime": "2022-08-01 10:07:30",
    "code": "688177"
  },
  {
    "title": "百奥泰2022年上半年预计亏损1.6亿-1.9亿同比由盈转亏 授权许可收入减少",
    "href": "http://stock.jrj.com.cn/2022/07/29231136855772.shtml",
    "datetime": "2022-07-29 23:11:34",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)半年度预亏1.6亿到1.9亿元",
    "href": "http://stock.jrj.com.cn/2022/07/29171636854243.shtml",
    "datetime": "2022-07-29 17:16:52",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：注射用BAT8010获批临床试验",
    "href": "http://stock.jrj.com.cn/2022/07/01155736775283.shtml",
    "datetime": "2022-07-01 15:57:46",
    "code": "688177"
  },
  {
    "title": "A股异动 | 百奥泰涨17% 治疗新冠肺炎注射用BAT2022获得临床试验批准",
    "href": "http://stock.jrj.com.cn/2022/06/13101136723061.shtml",
    "datetime": "2022-06-13 10:11:20",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：注射用BAT2022获批临床试验",
    "href": "http://stock.jrj.com.cn/2022/06/10170536719645.shtml",
    "datetime": "2022-06-10 17:05:15",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：拟与水牛建筑签署4587万元的建设工程施工合同",
    "href": "http://stock.jrj.com.cn/2022/06/08170236712766.shtml",
    "datetime": "2022-06-08 17:02:14",
    "code": "688177"
  },
  {
    "title": "百奥泰选举李胜峰担任公司董事长 2021年公司净利8193.65万",
    "href": "http://stock.jrj.com.cn/2022/05/20195236666978.shtml",
    "datetime": "2022-05-20 19:52:53",
    "code": "688177"
  },
  {
    "title": "百奥泰2021年净利8193.65万同比扭亏为盈 总经理李胜峰薪酬200.93万",
    "href": "http://stock.jrj.com.cn/2022/05/04155036556886.shtml",
    "datetime": "2022-05-04 15:50:43",
    "code": "688177"
  },
  {
    "title": "百奥泰2022年第一季度亏损1.1亿 同比亏损增加",
    "href": "http://stock.jrj.com.cn/2022/05/03203236547231.shtml",
    "datetime": "2022-05-03 20:32:41",
    "code": "688177"
  },
  {
    "title": "百奥泰披露2022年一季报 实现营收7422.06万元",
    "href": "http://stock.jrj.com.cn/2022/04/29084136500398.shtml",
    "datetime": "2022-04-29 08:41:50",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：贝伐珠单抗注射液(普贝希)新增3个适应症获批",
    "href": "http://stock.jrj.com.cn/2022/04/29075536499983.shtml",
    "datetime": "2022-04-29 07:55:27",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：一季度净亏损1.10亿元",
    "href": "http://stock.jrj.com.cn/2022/04/28222836496344.shtml",
    "datetime": "2022-04-28 22:28:13",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：2021年度净利润为8193.65万元 同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2022/04/28222636496347.shtml",
    "datetime": "2022-04-28 22:26:48",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：累计获得政府补助共5496.06万元",
    "href": "http://stock.jrj.com.cn/2022/04/19155736398497.shtml",
    "datetime": "2022-04-19 15:57:48",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：注射用BAT8009获得临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2022/04/15160236344707.shtml",
    "datetime": "2022-04-15 16:02:47",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：通过高新技术企业认定",
    "href": "http://stock.jrj.com.cn/2022/04/12171536315835.shtml",
    "datetime": "2022-04-12 17:15:00",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：美泊利珠单抗注射液(BAT2606)获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/03/25160535108634.shtml",
    "datetime": "2022-03-25 16:05:35",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：拟使用不超7.5亿元暂时闲置募集资金及不超4亿元自有资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/03/18171634845771.shtml",
    "datetime": "2022-03-18 17:16:38",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：980万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2022/03/18171334845737.shtml",
    "datetime": "2022-03-18 17:13:46",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：注射用BAT8006获得临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2022/03/09162134550514.shtml",
    "datetime": "2022-03-09 16:21:43",
    "code": "688177"
  },
  {
    "title": "百奥泰3名股东合计减持18万股 套现合计592.06万 2021年公司净利8517.85万",
    "href": "http://stock.jrj.com.cn/2022/03/03183234516872.shtml",
    "datetime": "2022-03-03 18:32:59",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：吉富启恒、合肥启兴和汇智富完成减持共18万股",
    "href": "http://stock.jrj.com.cn/2022/03/03160334516063.shtml",
    "datetime": "2022-03-03 16:03:32",
    "code": "688177"
  },
  {
    "title": "百奥泰2021年净利8517.85万同比扭亏为盈 积极拓展国内市场",
    "href": "http://stock.jrj.com.cn/2022/02/25183034465430.shtml",
    "datetime": "2022-02-25 18:30:34",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：183.1501万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2022/02/11164434323739.shtml",
    "datetime": "2022-02-11 16:44:38",
    "code": "688177"
  },
  {
    "title": "A股异动 | 百奥泰涨8% 料2021年度盈利6500万元-9500万元 同比扭亏",
    "href": "http://stock.jrj.com.cn/2022/01/28100934241588.shtml",
    "datetime": "2022-01-28 10:09:51",
    "code": "688177"
  },
  {
    "title": "百奥泰2021年预计净利6500万-9500万同比扭亏为盈 业务规模逐步扩大",
    "href": "http://stock.jrj.com.cn/2022/01/27193134231729.shtml",
    "datetime": "2022-01-27 19:31:46",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)2021年度预盈6500万-9500万元 同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2022/01/27185234231640.shtml",
    "datetime": "2022-01-27 18:52:30",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：收到由百济神州支付的3000万美元里程碑付款",
    "href": "http://stock.jrj.com.cn/2021/12/30204934088298.shtml",
    "datetime": "2021-12-30 20:49:47",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：阿达木单抗注射液获得药品补充申请批准通知书",
    "href": "http://stock.jrj.com.cn/2021/12/13163934008823.shtml",
    "datetime": "2021-12-13 16:39:16",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：减持期过半 吉富启恒、合肥启兴和汇智富已减持合计18万股",
    "href": "http://stock.jrj.com.cn/2021/12/06161233973879.shtml",
    "datetime": "2021-12-06 16:12:09",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：贝伐珠单抗注射液(普贝希)获批上市",
    "href": "http://stock.jrj.com.cn/2021/11/19164133880274.shtml",
    "datetime": "2021-11-19 16:41:29",
    "code": "688177"
  },
  {
    "title": "A股异动 | 百奥泰(688177.SH)涨逾4% 托珠单抗注射液(BAT1806)上市许可申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/11/09111233826948.shtml",
    "datetime": "2021-11-09 11:12:04",
    "code": "688177"
  },
  {
    "title": "百奥泰：托珠单抗注射液(BAT1806)上市许可申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/11/08165933823581.shtml",
    "datetime": "2021-11-08 16:59:44",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：托珠单抗注射液(BAT1806)上市许可申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/11/08165333823554.shtml",
    "datetime": "2021-11-08 16:53:23",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)第三季度净亏损1.14亿元",
    "href": "http://stock.jrj.com.cn/2021/10/27155733761463.shtml",
    "datetime": "2021-10-27 15:57:34",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：BAT7104注射液获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/10/19164533716782.shtml",
    "datetime": "2021-10-19 16:45:10",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：关联方水牛建筑中标奥泰研发中心及营销总部项目",
    "href": "http://stock.jrj.com.cn/2021/10/11175433673990.shtml",
    "datetime": "2021-10-11 17:54:25",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：拟终止发行H股股票并在香港联交所上市的申请",
    "href": "http://stock.jrj.com.cn/2021/09/17170333452092.shtml",
    "datetime": "2021-09-17 17:03:34",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：阿达木单抗注射液获得药品补充申请批准通知书",
    "href": "http://stock.jrj.com.cn/2021/09/17165933452041.shtml",
    "datetime": "2021-09-17 16:59:22",
    "code": "688177"
  },
  {
    "title": "百奥泰：签署BAT1706(贝伐珠单抗)注射液授权许可与商业化协议",
    "href": "http://stock.jrj.com.cn/2021/09/08193933405525.shtml",
    "datetime": "2021-09-08 19:39:26",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)与诺华达成伐珠单抗海外授权合作",
    "href": "http://stock.jrj.com.cn/2021/09/08185233405372.shtml",
    "datetime": "2021-09-08 18:52:19",
    "code": "688177"
  },
  {
    "title": "百奥泰2021年半年度净利261.62万元 同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2021/08/30113033350807.shtml",
    "datetime": "2021-08-30 11:30:34",
    "code": "688177"
  },
  {
    "title": "百奥泰将BAT2206注射液在美国市场独占的产品商业化权益有偿许可给 Hikma | 公司要闻",
    "href": "http://stock.jrj.com.cn/2021/08/27172033334060.shtml",
    "datetime": "2021-08-27 17:20:12",
    "code": "688177"
  },
  {
    "title": "百奥泰：将乌司奴单抗注射液在美国市场的独占的产品商业化权益有偿许可给Hikma",
    "href": "http://stock.jrj.com.cn/2021/08/27164933333734.shtml",
    "datetime": "2021-08-27 16:49:19",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)上半年实现净利261.62万元 同比扭亏",
    "href": "http://stock.jrj.com.cn/2021/08/27164433333656.shtml",
    "datetime": "2021-08-27 16:44:14",
    "code": "688177"
  },
  {
    "title": "百奥泰3名股东拟合计减持不超2105.85万股公司股份 一季度公司亏损1.09亿",
    "href": "http://stock.jrj.com.cn/2021/08/13203133250529.shtml",
    "datetime": "2021-08-13 20:31:58",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：吉富启恒等股东拟减持不超5.09%股份",
    "href": "http://stock.jrj.com.cn/2021/08/13165633249252.shtml",
    "datetime": "2021-08-13 16:56:41",
    "code": "688177"
  },
  {
    "title": "百奥泰2021年上半年预计净利230万-330万 药品销售收入增加",
    "href": "http://stock.jrj.com.cn/2021/07/29194533170852.shtml",
    "datetime": "2021-07-29 19:45:57",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：半年度净利预计为230万元-330万元",
    "href": "http://stock.jrj.com.cn/2021/07/29171033170064.shtml",
    "datetime": "2021-07-29 17:10:40",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：收到由Biogen支付的2859万美元首付款",
    "href": "http://stock.jrj.com.cn/2021/07/21184733130985.shtml",
    "datetime": "2021-07-21 18:47:55",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：在研药品BAT6005注射液临床试验获批",
    "href": "http://stock.jrj.com.cn/2021/07/20180233125119.shtml",
    "datetime": "2021-07-20 18:02:40",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：TIGIT单抗BAT6021获批临床",
    "href": "http://stock.jrj.com.cn/2021/07/08165233064660.shtml",
    "datetime": "2021-07-08 16:52:37",
    "code": "688177"
  },
  {
    "title": "百奥泰：BAT1706处于正常的审评程序中",
    "href": "http://stock.jrj.com.cn/2021/04/28110732469989.shtml",
    "datetime": "2021-04-28 11:07:24",
    "code": "688177"
  },
  {
    "title": "百奥泰：目前公司经营情况一切正常",
    "href": "http://stock.jrj.com.cn/2021/04/28103532469734.shtml",
    "datetime": "2021-04-28 10:35:59",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：一季度亏损收窄 净亏损1.09亿元",
    "href": "http://stock.jrj.com.cn/2021/04/27154832462838.shtml",
    "datetime": "2021-04-27 15:48:41",
    "code": "688177"
  },
  {
    "title": "百奥泰：在研药品BAT4706注射液获临床试验批准通知",
    "href": "http://stock.jrj.com.cn/2021/04/26114432453033.shtml",
    "datetime": "2021-04-26 11:44:19",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：BAT4706注射液获得临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/04/25165532438126.shtml",
    "datetime": "2021-04-25 16:55:39",
    "code": "688177"
  },
  {
    "title": "百奥泰与Biogen就BAT1806(托珠单抗)注射液签署授权许可与商业化协议",
    "href": "http://stock.jrj.com.cn/2021/04/09100032339606.shtml",
    "datetime": "2021-04-09 10:00:34",
    "code": "688177"
  },
  {
    "title": "原研药降价83% 格乐立能否充当百奥泰的“救命稻草”？",
    "href": "http://stock.jrj.com.cn/2021/03/31111732254599.shtml",
    "datetime": "2021-03-31 11:17:42",
    "code": "688177"
  },
  {
    "title": "百奥泰的背水一战：唯一品种上市碰上竞争对手降价83%",
    "href": "http://stock.jrj.com.cn/2021/03/31111732254600.shtml",
    "datetime": "2021-03-31 11:17:34",
    "code": "688177"
  },
  {
    "title": "全球临床试验模式“烧钱” 百奥泰董事长寄望赴港“补血”",
    "href": "http://stock.jrj.com.cn/2021/03/31111432254583.shtml",
    "datetime": "2021-03-31 11:14:51",
    "code": "688177"
  },
  {
    "title": "董事长年度股东大会表态不增持，寄望赴港“补血” 百奥泰研发窟窿如何填？",
    "href": "http://stock.jrj.com.cn/2021/03/31111432254569.shtml",
    "datetime": "2021-03-31 11:14:02",
    "code": "688177"
  },
  {
    "title": "百奥泰董事长易贤忠谈股价破发：对给投资者带去损失深表歉意，自身再增持意义不大",
    "href": "http://stock.jrj.com.cn/2021/03/26154332222732.shtml",
    "datetime": "2021-03-26 15:43:21",
    "code": "688177"
  },
  {
    "title": "港股IPO|生物制药公司百奥泰二次递表，2020年格乐立产品销售毛利率为89.1%",
    "href": "http://stock.jrj.com.cn/2021/03/25104632214321.shtml",
    "datetime": "2021-03-25 10:46:18",
    "code": "688177"
  },
  {
    "title": "百奥泰重新提交H股主板上市申请 阿达木单抗注射液获药品补充申请批准",
    "href": "http://stock.jrj.com.cn/2021/03/24112932207387.shtml",
    "datetime": "2021-03-24 11:29:04",
    "code": "688177"
  },
  {
    "title": "百奥泰：重新向港交所递交H股上市申请",
    "href": "http://stock.jrj.com.cn/2021/03/23213932204181.shtml",
    "datetime": "2021-03-23 21:39:38",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：阿达木单抗注射液获得药品补充申请批准",
    "href": "http://stock.jrj.com.cn/2021/03/23212332204128.shtml",
    "datetime": "2021-03-23 21:23:44",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：已向香港联交所重新递交H股发行的上市申请",
    "href": "http://stock.jrj.com.cn/2021/03/23212132204126.shtml",
    "datetime": "2021-03-23 21:21:41",
    "code": "688177"
  },
  {
    "title": "百奥泰成立18年仅一款药品上市 易贤忠重返A股股价一年跌逾70%",
    "href": "http://stock.jrj.com.cn/2021/03/16072732142210.shtml",
    "datetime": "2021-03-16 07:27:18",
    "code": "688177"
  },
  {
    "title": "新版医保目录实施半月 百奥泰终止PD-1研究、罗氏又撤回新适应症",
    "href": "http://stock.jrj.com.cn/2021/03/10185032104924.shtml",
    "datetime": "2021-03-10 18:50:19",
    "code": "688177"
  },
  {
    "title": "百奥泰、先惠技术昨日召开业绩说明会",
    "href": "http://stock.jrj.com.cn/2021/03/09095532096239.shtml",
    "datetime": "2021-03-09 09:55:27",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)2020年营收达1.85亿元 投入研发费用5.63亿元",
    "href": "http://stock.jrj.com.cn/2021/03/05130232077650.shtml",
    "datetime": "2021-03-05 13:02:04",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)决定终止BAT8003及BAT1306临床试验",
    "href": "http://stock.jrj.com.cn/2021/03/05124232077564.shtml",
    "datetime": "2021-03-05 12:42:17",
    "code": "688177"
  },
  {
    "title": "百奥泰：拟终止BAT8003及BAT1306临床试验 去年亏损超5亿",
    "href": "http://stock.jrj.com.cn/2021/03/05102332076909.shtml",
    "datetime": "2021-03-05 10:23:56",
    "code": "688177"
  },
  {
    "title": "百奥泰募资20亿上市首年亏损5亿破发 中金等赚7783万",
    "href": "http://stock.jrj.com.cn/2021/03/03182232064771.shtml",
    "datetime": "2021-03-03 18:22:00",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)业绩快报：2020年度净亏损5.13亿元",
    "href": "http://stock.jrj.com.cn/2021/02/26160632033133.shtml",
    "datetime": "2021-02-26 16:06:39",
    "code": "688177"
  },
  {
    "title": "百奥泰：阿达木单抗注射液获批新增适应症",
    "href": "http://stock.jrj.com.cn/2021/02/21161931999233.shtml",
    "datetime": "2021-02-21 16:19:17",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：阿达木单抗注射液获得药品补充申请批准通知书",
    "href": "http://stock.jrj.com.cn/2021/02/21154831999165.shtml",
    "datetime": "2021-02-21 15:48:03",
    "code": "688177"
  },
  {
    "title": "百奥泰跌18.7%：巨杉资产持股 上月东方财富喊增持",
    "href": "http://stock.jrj.com.cn/2021/02/09174531878276.shtml",
    "datetime": "2021-02-09 17:45:00",
    "code": "688177"
  },
  {
    "title": "百奥泰：目前公司新增生产线已完成现场设备的建设",
    "href": "http://stock.jrj.com.cn/2021/02/09132631876821.shtml",
    "datetime": "2021-02-09 13:26:14",
    "code": "688177"
  },
  {
    "title": "百奥泰：中国证监会授予的公司境外股票发行和上市申报文件的有效期为12个月",
    "href": "http://stock.jrj.com.cn/2021/02/09132531876820.shtml",
    "datetime": "2021-02-09 13:25:58",
    "code": "688177"
  },
  {
    "title": "百奥泰终止BAT8001项目临床试验，已累计投入2.26亿元",
    "href": "http://stock.jrj.com.cn/2021/02/09115431876520.shtml",
    "datetime": "2021-02-09 11:54:33",
    "code": "688177"
  },
  {
    "title": "A股异动 | 百奥泰(688177.SH)大跌超17%创新低 终止BAT8001临床试验",
    "href": "http://stock.jrj.com.cn/2021/02/09102031875968.shtml",
    "datetime": "2021-02-09 10:20:23",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：终止BAT8001临床试验",
    "href": "http://stock.jrj.com.cn/2021/02/08202831872061.shtml",
    "datetime": "2021-02-08 20:28:55",
    "code": "688177"
  },
  {
    "title": "百奥泰：III期数据未达到预设目标 抗肿瘤新药BAT8001的临床试验终止",
    "href": "http://stock.jrj.com.cn/2021/02/08201731872008.shtml",
    "datetime": "2021-02-08 20:17:43",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：BAT8001 III期临床试验未达预期",
    "href": "http://stock.jrj.com.cn/2021/02/08162331870490.shtml",
    "datetime": "2021-02-08 16:23:21",
    "code": "688177"
  },
  {
    "title": "百奥泰：在研药司库奇尤单抗获批进行临床试验",
    "href": "http://stock.jrj.com.cn/2021/02/08091531868111.shtml",
    "datetime": "2021-02-08 09:15:08",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：司库奇尤单抗(BAT2306)注射液的临床试验获批",
    "href": "http://stock.jrj.com.cn/2021/02/07163231861148.shtml",
    "datetime": "2021-02-07 16:32:47",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：3774.3423万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2021/02/05175231855450.shtml",
    "datetime": "2021-02-05 17:52:48",
    "code": "688177"
  },
  {
    "title": "百奥泰：收到多国家及地区颁发的专利证书",
    "href": "http://stock.jrj.com.cn/2021/01/07102531646405.shtml",
    "datetime": "2021-01-07 10:25:21",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)：公司近日获得5项发明专利证书",
    "href": "http://stock.jrj.com.cn/2021/01/06163831641948.shtml",
    "datetime": "2021-01-06 16:38:57",
    "code": "688177"
  },
  {
    "title": "百奥泰：新产线完成后 公司抗体原液总生产能力将增加到约1250 kg",
    "href": "http://stock.jrj.com.cn/2020/11/20132331323158.shtml",
    "datetime": "2020-11-20 13:23:03",
    "code": "688177"
  },
  {
    "title": "百奥泰：目前公司尚未开展广谱疫苗项目",
    "href": "http://stock.jrj.com.cn/2020/11/20104631322072.shtml",
    "datetime": "2020-11-20 10:46:46",
    "code": "688177"
  },
  {
    "title": "[百奥泰]特别提示",
    "href": "http://stock.jrj.com.cn/2020/11/11000031258616.shtml",
    "datetime": "2020-11-11 00:00:00",
    "code": "688177"
  },
  {
    "title": "百奥泰：2020年前三季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/10/30011031162925.shtml",
    "datetime": "2020-10-30 01:10:20",
    "code": "688177"
  },
  {
    "title": "百奥泰(688177.SH)拟使用不超1亿元闲置募集资金暂补流动资金",
    "href": "http://stock.jrj.com.cn/2020/09/21161530803019.shtml",
    "datetime": "2020-09-21 16:15:18",
    "code": "688177"
  },
  {
    "title": "百奥泰：2020年第三次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/09/11135030729258.shtml",
    "datetime": "2020-09-11 13:50:01",
    "code": "688177"
  },
  {
    "title": "百奥泰2020年上半年亏损2.44亿亏损减少 去年同期无营业收入",
    "href": "http://stock.jrj.com.cn/2020/08/28154230614348.shtml",
    "datetime": "2020-08-28 15:42:27",
    "code": "688177"
  },
  {
    "title": "百奥泰拟港股上市 康希诺生物明日将正式登陆科创板 | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/08/12194930484248.shtml",
    "datetime": "2020-08-12 19:49:16",
    "code": "688177"
  },
  {
    "title": "国家药监局召开会议研究部署下半年工作 百奥泰授权Pharmapark独家商业化其戈利木单抗 | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/07/17184530275732.shtml",
    "datetime": "2020-07-17 18:45:43",
    "code": "688177"
  },
  {
    "title": "科创板募资20亿 百奥泰再谋港股上市",
    "href": "http://stock.jrj.com.cn/kcb/2020/06/22043629980987.shtml",
    "datetime": "2020-06-22 04:36:23",
    "code": "688177"
  },
  {
    "title": "百奥泰启动H股上市进程 科创板创新药企欲“A+H”阔步国际化",
    "href": "http://stock.jrj.com.cn/kcb/2020/06/17073029946278.shtml",
    "datetime": "2020-06-17 07:30:54",
    "code": "688177"
  },
  {
    "title": "百奥泰：第一届董事会第十六次会议决议公告",
    "href": "http://stock.jrj.com.cn/2020/06/17005029941736.shtml",
    "datetime": "2020-06-17 00:50:00",
    "code": "688177"
  },
  {
    "title": "百奥泰筹划发行H股股票并在香港上市",
    "href": "http://stock.jrj.com.cn/2020/06/16185229939784.shtml",
    "datetime": "2020-06-16 18:52:01",
    "code": "688177"
  },
  {
    "title": "百奥泰：公司筹划发行H股股票并在香港上市事项经董事会审议通过",
    "href": "http://stock.jrj.com.cn/2020/06/16155129938354.shtml",
    "datetime": "2020-06-16 15:51:56",
    "code": "688177"
  },
  {
    "title": "百奥泰BAT1308注射液获得临床试验通知",
    "href": "http://stock.jrj.com.cn/2020/05/27174429779876.shtml",
    "datetime": "2020-05-27 17:44:51",
    "code": "688177"
  },
  {
    "title": "百奥泰：2019年年度股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/05/20003029715278.shtml",
    "datetime": "2020-05-20 00:30:21",
    "code": "688177"
  },
  {
    "title": "逾三成A股药企销售费用率超30% 百奥泰居首",
    "href": "http://stock.jrj.com.cn/2020/05/18013929694003.shtml",
    "datetime": "2020-05-18 01:39:41",
    "code": "688177"
  },
  {
    "title": "百奥泰：获得一项发明专利证书 系公司重要核心技术的体现和延伸",
    "href": "http://stock.jrj.com.cn/2020/05/08174229619871.shtml",
    "datetime": "2020-05-08 17:42:32",
    "code": "688177"
  },
  {
    "title": "百奥泰：获广州开发区金融工作局500万元境内外资本市场上市奖励",
    "href": "http://stock.jrj.com.cn/2020/03/26184029119919.shtml",
    "datetime": "2020-03-26 18:40:38",
    "code": "688177"
  },
  {
    "title": "百奥泰获得境内外资本市场上市奖励共计人民币500万元",
    "href": "http://stock.jrj.com.cn/2020/03/26175029119550.shtml",
    "datetime": "2020-03-26 17:50:28",
    "code": "688177"
  },
  {
    "title": "百奥泰获得政府补助500万元",
    "href": "http://stock.jrj.com.cn/2020/03/26172829119001.shtml",
    "datetime": "2020-03-26 17:28:43",
    "code": "688177"
  },
  {
    "title": "百奥泰：获得政府补助500万元",
    "href": "http://stock.jrj.com.cn/2020/03/26163329118612.shtml",
    "datetime": "2020-03-26 16:33:12",
    "code": "688177"
  },
  {
    "title": "百奥泰：重组抗VEGF人源化单克隆抗体注射液获临床试验通知书",
    "href": "http://stock.jrj.com.cn/2020/03/02203828936205.shtml",
    "datetime": "2020-03-02 20:38:38",
    "code": "688177"
  },
  {
    "title": "百奥泰：重组抗VEGF人源化单克隆抗体注射液获得临床试验通知书",
    "href": "http://stock.jrj.com.cn/2020/03/02202028936160.shtml",
    "datetime": "2020-03-02 20:20:00",
    "code": "688177"
  },
  {
    "title": "百奥泰重组抗VEGF人源化单克隆抗体注射液获得临床试验通知",
    "href": "http://stock.jrj.com.cn/2020/03/02201728936150.shtml",
    "datetime": "2020-03-02 20:17:47",
    "code": "688177"
  },
  {
    "title": "上市公司晚间利空汇总：百奥泰2019年净利润亏损10亿元",
    "href": "http://stock.jrj.com.cn/2020/02/26181928898391.shtml",
    "datetime": "2020-02-26 18:19:49",
    "code": "688177"
  },
  {
    "title": "百奥泰：2019年亏损10.24亿元",
    "href": "http://stock.jrj.com.cn/2020/02/26174728898248.shtml",
    "datetime": "2020-02-26 17:47:49",
    "code": "688177"
  },
  {
    "title": "科创板百奥泰业绩快报：2019年净利润亏损10亿元",
    "href": "http://stock.jrj.com.cn/2020/02/26164328897867.shtml",
    "datetime": "2020-02-26 16:43:23",
    "code": "688177"
  },
  {
    "title": "百奥泰：提升行业优势 促进在研产品向商业化转型",
    "href": "http://stock.jrj.com.cn/2020/02/21143328870959.shtml",
    "datetime": "2020-02-21 14:33:00",
    "code": "688177"
  },
  {
    "title": "阿达木单抗国产获批 今日科创板上市的百奥泰能否续写药王传奇？",
    "href": "http://stock.jrj.com.cn/kcb/2020/02/21095428869374.shtml",
    "datetime": "2020-02-21 09:54:35",
    "code": "688177"
  },
  {
    "title": "百奥泰上市 开盘上涨83.15%",
    "href": "http://stock.jrj.com.cn/2020/02/21093528869165.shtml",
    "datetime": "2020-02-21 09:35:36",
    "code": "688177"
  },
  {
    "title": "2月21日新股提示：石头科技、百奥泰、神工股份上市 建业股份中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2020/02/21082728868775.shtml",
    "datetime": "2020-02-21 08:27:03",
    "code": "688177"
  },
  {
    "title": "科创板百奥泰中签号出炉 共34674个",
    "href": "http://stock.jrj.com.cn/2020/02/12192828817326.shtml",
    "datetime": "2020-02-12 19:28:00",
    "code": "688177"
  },
  {
    "title": "【兑奖啦】百奥泰网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2020/02/12191128817269.shtml",
    "datetime": "2020-02-12 19:11:49",
    "code": "688177"
  },
  {
    "title": "【兑奖啦】神工股份、石头科技、百奥泰网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2020/02/12191028817266.shtml",
    "datetime": "2020-02-12 19:10:38",
    "code": "688177"
  },
  {
    "title": "百奥泰网上发行最终中签率为0.0467%",
    "href": "http://stock.jrj.com.cn/ipo/2020/02/12083728813587.shtml",
    "datetime": "2020-02-12 08:37:59",
    "code": "688177"
  },
  {
    "title": "神工股份、石头科技、百奥泰三新股中签率出炉",
    "href": "http://stock.jrj.com.cn/ipo/2020/02/11225428811729.shtml",
    "datetime": "2020-02-11 22:54:30",
    "code": "688177"
  },
  {
    "title": "百奥泰IPO：网上中签率0.04666639%",
    "href": "http://stock.jrj.com.cn/2020/02/11201228811198.shtml",
    "datetime": "2020-02-11 20:12:40",
    "code": "688177"
  },
  {
    "title": "石头科技网上发行最终中签率为0.04186742％",
    "href": "http://stock.jrj.com.cn/ipo/2020/02/11191828810986.shtml",
    "datetime": "2020-02-11 19:18:08",
    "code": "688177"
  },
  {
    "title": "百奥泰：网上发行最终中签率为0.04666639％",
    "href": "http://stock.jrj.com.cn/ipo/2020/02/11190928810962.shtml",
    "datetime": "2020-02-11 19:09:22",
    "code": "688177"
  },
  {
    "title": "百奥泰2月11日开启申购",
    "href": "http://stock.jrj.com.cn/2020/02/11115928808402.shtml",
    "datetime": "2020-02-11 11:59:00",
    "code": "688177"
  },
  {
    "title": "科创板新股神工股份、百奥泰、石头科技2月11日申购宝典",
    "href": "http://stock.jrj.com.cn/kcb/2020/02/10141128802668.shtml",
    "datetime": "2020-02-10 14:11:04",
    "code": "688177"
  },
  {
    "title": "百奥泰：致力于成为新一代抗体药物研发的引领者",
    "href": "http://stock.jrj.com.cn/2020/02/03161528756426.shtml",
    "datetime": "2020-02-03 16:15:00",
    "code": "688177"
  },
  {
    "title": "百奥泰获科创板上市注册批文 将登陆科创板",
    "href": "http://stock.jrj.com.cn/2020/01/23211828729191.shtml",
    "datetime": "2020-01-23 21:18:00",
    "code": "688177"
  },
  {
    "title": "百奥泰启动招股 手持第五套标准“入场券”走向科创板",
    "href": "http://stock.jrj.com.cn/kcb/2020/01/23073628725400.shtml",
    "datetime": "2020-01-23 07:36:46",
    "code": "688177"
  },
  {
    "title": "石头科技与百奥泰成功闯关 科创板过会企业向百家挺进",
    "href": "http://stock.jrj.com.cn/kcb/2019/11/21074128430003.shtml",
    "datetime": "2019-11-21 07:41:25",
    "code": "688177"
  },
  {
    "title": "科创板上市委：百奥泰、石头科技首发通过",
    "href": "http://stock.jrj.com.cn/2019/11/20170828427581.shtml",
    "datetime": "2019-11-20 17:08:00",
    "code": "688177"
  },
  {
    "title": "百奥泰科创板上会在即 重磅产品或面临激烈竞争",
    "href": "http://stock.jrj.com.cn/2019/11/14144428399274.shtml",
    "datetime": "2019-11-14 14:44:51",
    "code": "688177"
  },
  {
    "title": "科创板上市委：百奥泰、石头科技11月20日首发上会",
    "href": "http://stock.jrj.com.cn/2019/11/11172028380688.shtml",
    "datetime": "2019-11-11 17:20:00",
    "code": "688177"
  },
  {
    "title": "每经小强快讯：前往科创板再下一城，百奥泰生物制药股份有限公司已获上交所问询",
    "href": "http://stock.jrj.com.cn/2019/08/05201127931914.shtml",
    "datetime": "2019-08-05 20:11:12",
    "code": "688177"
  },
  {
    "title": "卖壳分众传媒后 易贤忠携百奥泰生物制药再度冲击科创板",
    "href": "http://stock.jrj.com.cn/kcb/2019/07/29080227897271.shtml",
    "datetime": "2019-07-29 08:02:12",
    "code": "688177"
  },
  {
    "title": "第二家！百奥泰选用科创板第五套上市标准",
    "href": "http://stock.jrj.com.cn/2019/07/09065327814534.shtml",
    "datetime": "2019-07-09 06:53:00",
    "code": "688177"
  },
  {
    "title": "每经小强快讯：百奥泰生物制药股份有限公司科创板首次公开发行股票招股说明书（申报稿）",
    "href": "http://stock.jrj.com.cn/2019/07/08190227810541.shtml",
    "datetime": "2019-07-08 19:02:01",
    "code": "688177"
  },
  {
    "title": "每经小强快讯：进军科创板，百奥泰生物制药股份有限公司申请已获上交所受理",
    "href": "http://stock.jrj.com.cn/2019/07/08190127810546.shtml",
    "datetime": "2019-07-08 19:01:57",
    "code": "688177"
  },
  {
    "title": "安图生物2亿元收购百奥泰康 切入生化类体外诊断领域",
    "href": "http://stock.jrj.com.cn/2017/05/10003122453132.shtml",
    "datetime": "2017-05-10 00:31:00",
    "code": "688177"
  }
]